StockMarketWire.com - Drug development group Venn Life Sciences said it had formed a partnership with Carrick Therapeutics to help it develop cancer treatments.

Carrick Therapeutics had built a network of partners and collaborators to progress its technology portfolio, with Venn joining the network as a provider of early development and clinical research capabilities.

'In so many respects Carrick Therapeutics represents the model client for Venn,' chief executive Tony Richardson said.

'Highly innovative with a portfolio approach focusing on their core IP while working on an outsource basis with a well-developed network of support partners.'

'At Venn we have built a suite of capabilities designed to address all of the development requirements of this model and are delighted to partner with Carrick in the development of their first in class treatments.'


At 8:07am: [LON:VENN] Venn Life Sciences Holdings PLC share price was +0.2p at 2p



Story provided by StockMarketWire.com